Clinical Trial: Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07873996) titled 'Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma' on Aug. 06.

Brief Summary: This is an investigator-initiated, randomized, open-label, parallel-controlled clinical study designed to evaluate the efficacy and safety of locally administered Tris-CAR-T cells in adults with newly diagnosed glioblastoma.

A total of 60 postoperative participants with IDH-wildtype WHO CNS grade 4 glioblastoma will be randomized 1:1 to the experimental group or the control group, with 30 participants in each group.

Participants in the experimental group will receive Ommaya reservoir implantation followed by local intratumo...